On May 12, 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical (C-RNA) for leave to appeal (Docket No. 39994) a decision of the Federal Court of Appeal relating to the refusal of a Natural Health Product (NHP) licence for C-RNA’s oral lumbrokinase capsules (BOLUOKE).
As previously reported, the Federal Court of Appeal did not find any reviewable error in the decision of the Minister of Health (Minister) to refuse granting an NHP licence for BOLUOKE or in the Federal Court’s reasoning in dismissing C-RNA’s application for judicial review of the Minister’s decision.
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada proposes amendments to the Food and Drug Regulations and Medical Devices Regulations to modernize framework for therapeutic product recalls
On April 15, 2023, Health Canada proposed amendments to the Food and Drug Regulations and the Medical Devices Regulations (together, the “Proposed Amendments”).Read More -
Proposed legislation for patent term adjustment, and the interplay with CSPs
Bill C-47 is an omnibus bill that includes proposed amendments to the Patent Act to introduce patent term adjustment to compensate the patentee for Patent Office delays in granting a patent.Read More -
Health Canada publishes revised Guidance Document: Certificates of Supplementary Protection (CSP)
On May 12, 2023, Health Canada announced the fifth version of the Guidance Document: Certificates of Supplementary Protection. The changes are desRead More